The present findings suggest that the role of irisin as a protective myo‐adipokine in atypical metabolic situations needs further examination, but provides promising support for the potential pharmacotherapeutic use of irisin in the treatment of obesity and type 2 diabetes. The gene discussed is FNDC5; the disease is obesity due to melanocortin 4 receptor deficiency.